Moleculin Announces Memorial Sloan Kettering Chief of Leukemia Joins Science Advisory Board
HOUSTON, March 18, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Dr. Martin Tallman, Chief of...
Moleculin Biotech, Inc. to Present at the Oppenheimer 29th Annual Healthcare Conference and the 31st Annual ROTH Conference
HOUSTON, March 18, 2019 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018
HOUSTON, Feb. 21, 2019 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development
HOUSTON, Feb. 20, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Announces Approval for Third Drug to Commence Clinical Trials
MBRX will now have three distinctive oncology drugs in clinic in four ongoing clinical trials WP1220, a STAT3 inhibitor, to begin clinical trials in Poland for the treatment of Cutaneous T-Cell Lymphona ("CTCL"), a rare and deadly skin cancer HOUSTON, Feb. 07, 2019 --...
Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug
HOUSTON, Feb. 05, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board
Dr. Abbruzzese to add significant pancreatic cancer expertise to advance drug development HOUSTON, Jan. 17, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology...
Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland
Received European approval to ship Annamycin into Poland to start treating patients HOUSTON, Jan. 09, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate
WP1732 now second lead drug demonstrating enhanced activity in combination with immune checkpoint blockade antibodies HOUSTON, Jan. 03, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on...
REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018
HOUSTON, Dec. 11, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...